<code id='1242E2F662'></code><style id='1242E2F662'></style>
    • <acronym id='1242E2F662'></acronym>
      <center id='1242E2F662'><center id='1242E2F662'><tfoot id='1242E2F662'></tfoot></center><abbr id='1242E2F662'><dir id='1242E2F662'><tfoot id='1242E2F662'></tfoot><noframes id='1242E2F662'>

    • <optgroup id='1242E2F662'><strike id='1242E2F662'><sup id='1242E2F662'></sup></strike><code id='1242E2F662'></code></optgroup>
        1. <b id='1242E2F662'><label id='1242E2F662'><select id='1242E2F662'><dt id='1242E2F662'><span id='1242E2F662'></span></dt></select></label></b><u id='1242E2F662'></u>
          <i id='1242E2F662'><strike id='1242E2F662'><tt id='1242E2F662'><pre id='1242E2F662'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:leisure time    Page View:32
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more
          PBM executives asked to testify by House panel
          PBM executives asked to testify by House panel

          Rep.JamesComer(R-Ky.),thechairoftheHouseCommitteeonOversightandAccountability,hastakenaninterestinph

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

          Wanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyourinb